Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Trevena in a report on Thursday, November 14th.

Trevena Stock Down 12.4 %

TRVN stock opened at $1.62 on Monday. The stock has a market cap of $1.40 million, a price-to-earnings ratio of -0.03 and a beta of 1.05. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23. The business has a 50 day moving average price of $1.71 and a 200 day moving average price of $3.43.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The company had revenue of $0.28 million for the quarter. As a group, sell-side analysts anticipate that Trevena will post -23.04 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.